Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5635 in chronic hepatitis B
NCT06425341Phase 2Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Aug 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of HRS-5635 in Chronic Hepatitis B (CHB) (9 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Change in mean log10 serum hepatitis B surface antigen levels from baseline at 12 weeks and Proportion of subjects with serum hepatitis B surface antigen loss at 48 weeks. Started Jun 2024; status: recruiting.
02
Drugs
HRS-5635
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06425341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425341.